Sellas presents preclinical data on SLS009 CDK9 inhibitor in pancreatic cancer organoid models at AACR conference
Bitget2026/09/25 17:00- Sellas Life Sciences disclosed preclinical pancreatic cancer data for SLS009, a CDK9 inhibitor, from patient-derived organoid studies.
- Results are being presented at the AACR Conference on Pancreatic Cancer, running Sept. 25-28, 2026, in San Diego.
- SLS009 showed stronger single-agent anti-tumor activity than a RAS inhibitor in a resistant, MYC-amplified pancreatic cancer model.
- Combining SLS009 with the RAS inhibitor increased cancer cell death, supporting a potential strategy to address resistance to RAS-directed therapy.
- A separate study pairing SLS009 with BET inhibition produced synergistic activity, consistent with suppressing MYC-driven survival programs.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Besent “Extinguishes Fire”: Rising US Treasury yields are a global phenomenon, dismisses concerns over AI bubble
U.S. Treasury Secretary Janet Yellen defended the rise in U.S. Treasury yields, stating that this increase is a global phenomenon rather than unique to the United States, and does not warrant excessive concern. She partially attributed inflationary pressures to higher oil prices caused by the Iran conflict, and expects the energy shock to subside as hostilities ease. Yellen refuted the notion of an AI bubble, arguing that investments by major tech companies are grounded in solid business logic.
Bitcoin Crash Warning Goes Viral as X Post Flags Benner Cycle
"New High" WLD rises to $0.6177, reaching a nearly 3-month peak
Raoul Pal says the trend of asset tokenization is unstoppable.
Crypto prices
More
